At the news
? BULLISHIMPACT 7/10 6-K filed Sep 1, 2026 at 07:27 ET
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received EU approval for 1st-line treatment of HER2-positive metastatic breast cancer, based on the DESTINY-Breast09 Phase III trial showing a 44% reduction in risk of disease progression or death vs. standard of care (THP). This approval triggers a $100 million milestone payment from AstraZeneca to Daiichi Sankyo. Separately, AstraZeneca appointed Wan Ling Martello as a Non-Executive Director and Audit Committee member, a routine board change with no material financial impact.
- Enhertu plus pertuzumab approved in the EU for 1st-line treatment of HER2-positive metastatic breast cancer.
- Approval based on DESTINY-Breast09 Phase III trial showing 44% reduction in risk of disease progression or death (HR 0.56; p<0.00001) vs. THP.
- Median progression-free survival was 40.7 months with Enhertu combination vs. 26.9 months with THP.
- A $100 million milestone payment is due from AstraZeneca to Daiichi Sankyo following this EU approval.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access